p53 as a prognostic marker in carcinoma breast in correlation with conventional estrogen and progesterone hormone receptors

  • Sanjay Piplani Associate Professor Department of Pathology Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab
  • Manas Madaan
  • Mridu Manjari
  • Rahul Manan
Keywords: Estrogen Receptor, Progesterone Receptor, p53, Tumor Grading, Lymph Node

Abstract

Background: Carcinoma breast is the most common cancer in women worldwide. The present study was done with the objective to find expression and correlation of Estrogen Receptors(ER), Progesterone Receptors(PR) and  p53 in breast carcinoma and to correlate expression of these tumor markers with histological type, grade and other parameters.Methods: The study was conducted on 65cases of breast cancer in the department of Pathology of a tertiary health care center. Histopathological and IHC studies were done for ER, PR and p53 expression, brown nuclei were taken as positive results and IHC Scoring was done.Results: All the cases were of Infiltrating Ductal Carcinomas(NOS) between 30-70years of age with varying tumor size1-6cm. Maximum cases were of grade III followed by grade II. Metastatic carcinomatous deposits in Lymph nodes were seen in 42cases. On the basis of ER PR positivity, tumors were separated into 4 categories with category IV having maximum number of cases. ER/PR expression in grade III cases was significantly low. With increasing grade, the expression of p53 increased which was statistically significant p=0.007. Lymph nodes showing metastatic deposits were highest in ER PR negative cases which was statistically significant(p=0.028). p53 expression was higher in category IV cases(32.3%) as compared to category I(15.4%).Conclusion: In the present study it was observed that as the grade increases, ER PR decreases and p53 positivity increases. Thus ER PR status is inversely proportional to p53 expression and emphasizes the need to find out the prognosis, survival and line of treatment.

Author Biography

Sanjay Piplani, Associate Professor Department of Pathology Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar, Punjab
Associate ProfessorDepartment of Pathology

References

1. Khokhar A. Breast Cancer in India: Where Do We Stand and Where Do We Go? Asian Pacific J Cancer Prev. 2012;13(10):4861-6.
2. Breast Cancer Facts [Internet]. Texas: National Breast Cancer Foundation; 2015;12 [cited 2015 sep 12]. Available from: http://www.nationalbreastcancer.org/breast-cancer-facts.
3. Breast cancer incidence statistics [Internet]. London: Cancer Research UK. 2015;15 [cited 2015 Aug 25]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence.
4. Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007;31(5):1031-40.
5. Meshram II, Hiwarkar PA, Kulkarni PN. Reproductive risk factors for breast cancer: a case control study. Online J Health Allied Scs. 2009;8(3):5.
6. Gajalakshmi V, Mathew A, Brennan P, et al. Breast feeding and breast cancer risk in India: a multicenter case-control study. Int J Cancer. 2009;125(3):662-5.
7. Singh MM, Devi R, Walia I, Kumar R. Breast self examination for early detection of breast cancer. Indian J Med Sci. 1999;53(3):120-6.
8. Tavani A, Gallus S, La-Vecchia C, et al. Risk factors for breast cancer in women under 40 years. Eur J Cancer. 1999;35(9):1361-7.
9. Jeffery SR. Predictive and prognostic molecular markers in breast cancer. In: Lowe DG, Underwood JCE, editors. Recent Advances in Histopathology. London: Royal Society of Medicine Press Ltd; 2005. p. 31-50.
10. Rosai J. The Breast. In: Rosai and Ackerman’s Surgical Pathology. 10th Edition (Vol.2). New York: Mosby (Elsevier); 2012. p.1719-20.
11. Gadkar-Sable S, Shah C, Rosario G, Sachdeva G, Puri C. Progesterone Receptors, various forms and functions in reproductive tissues. Frontier Biosciences. 2005;10:2118-30.
12. Onitilo AA, Engel JM, Greenlee R T, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res. 2009;7(1-2):4–13.
13. Lee SK, Bae SY, Lee JH, et al. Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival. PLoS One. 2015;10(8):e0124658.
14. Lacroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13(2):293-325.
15. Ahmed HG, Al-Adhraei MA, Al-Thobhani AK. Correlations of Hormone Receptors (ER and PR), Her2/neu and p53 Expression in Breast Ductal Carcinoma Among Yemeni Women.The Open Cancer Immunology Journal. 2011;4:1-9.
16. Komen SG. Breast Cancer Facts [Internet]. Dallas: Susan G. Komen; [cited 2013 Nov 14]. Available from: http://ww5.komen.org/uploaded Files/Content_Binaries/806-316a.pdf.
17. Shetty P. India faces growing breast cancer epidemic. The Lancet. 2012;379(9820):992-3.
18. Kaur G, Ismail R, Kam LS, Sabaratnam S, Ahmad N. Assessment of correlation between Clinicopathological Features and Lymph Node Metastasis in Breast Cancer. The Internet J Pathol. 2007;5:2.
19. Saleh F, Abdeen S. Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog. 2007;6:12.
20. Hussain MA, Ali S, Tyagi SP, Reza H. Incidence of cancer breast at Aligarh. J Indian Med Assoc. 1994;92(9):296-7.
21. Lee AH. Why is carcinoma of the breast more frequent in the upper outer quadrant? A case series based on needle core biopsy diagnoses. Breast. 2005;14(2):151-2.
22. Shaheen G, Arshad M, Shamim T, et al. Prevalence Of Breast Cancer In Punjab. The Internet Journal of Public Health. 2011;1(1):88-93.
23. Lester SC. The Breast. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors.Robbins and Cotran Pathologic Basis of Disease. 8th Ed. Philadelphia.Elsevier; 2010. p. 1066-90.
24. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T. Do we need Her-2/ neu testing for all patients with primary breast carcinoma? Cancer. 2003;98(12):547-53.
25. Hanif M, Sabeen B, Maqbool A, Ahmed A, Nadeem F, Habib S. Breast Cancer: Incidence (Thirteen Year Data Analysis) and (OneYear Clinicopathological Data) of Patients In a Tertiary Care Cancer Hospital. 2015;12(3):373-79.23.
26. Siddiqui MS, Kayani N, Sulaiman S, Hussainy AS, Shah SH, Muzaffar S. Breast carcinoma in Pakistani females: a morphological study of 572 breast specimens. J Pak Med Assoc. 2000;50(6):174-7.
27. Tan EY, Wong HB, Ang BK, Chan MYP. Locally advanced and metastatic breast cancer in a tertiary hospital. Ann Acad Med Singapore 2005;34(10):595-601.
28. Nisa A, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/ neu (C- erb B2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev. 2008;9(4):553-6.
29. Kamil M, Khalid I, Hashim H, Biswas M, Kaur G, Islam R. Association of carcinoma breast: grade and estrogen progesterone receptor expression. J Coll Physicians Surg Pak. 2010;20(4):250-2.
30. Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev. 2011;12(3):625-9.
31. Shokouh TZ, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. Medicine (Baltimore). 2015;94(32):e1359.
32. Bojić T, Djordjević N, Karanikolić A, Filipović S, Granić M, Poultsidi AA. Assessment of axillary lymph nodes involvement in patients with breast cancer depending on the tumor size and its histological and nuclear grades. Vojnosanit Pregl. 2012;69(5):414-9.
33. Fisher ER, Redmond CK, Liu H, Rockette H, Fisher B. Correlation of Estrogen Receptor and pathologic characteristics of invasive Breast Cancer. Cancer. 1980;45(2):349-53.
34. Manjunath S, Prabhu JS, Kaluve R, Correa M, Sridhar TS. Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype? Indian J Surg Oncol. 2011;2(2):122-5.
35. Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: A study of 798 tumours. Breast. 2000;9(5):267–70.
36. Mudduwa LK. Quick score of hormone receptor status of breast carcinoma: Correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol. 2009;52(2):159–63.
37. Stierer M, Rosen H, Weber R, Hanak H, Spona J, Fuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg. 1993;218(1):13–21.
38. Patnayak R, Jena A, Rukmangadha N, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36(2):117–22.
39. Mohammed R H, Lakatua D J, Haus E, Yasmineh WJ. Estrogen and progesterone receptors in human breast cancer: Correlation with histologic subtype and degree of differentiation. Cancer. 1986;58 (5):1076-81.
40. Barnes DM, Millis RR, Beex LVAM, Thorpe SM, Leake RE. Increased use of immunohistochemistry for estrogen receptor measurement in mammary carcinoma: The need for quality assurance. Eur J Cancer. 1998;34 (11):1677-82.
41. Jovicić-Milentijević M, Ilić R, Katić V, Zivković V. Correlation of steroid hormone receptor status with histological and nuclear grading in breast carcinoma. J BUON. 2004;9(2):173-7.
42. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003;21(10):1973-9.
43. Ali EM, Ahmed ARH, Ali AMA. Correlation of Breast Cancer Subtypes Based on ER, PR and HER2 Expression with Axillary Lymph Node Status. Cancer and Oncology Research. 2014;2(4):51-7.
44. Dunnwald LK, Rossing MK, Christopher I Li. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.Breast Cancer Res. 2007;9(1):R6.
45. Sirvent JJ, Salvadól MT, Santafé M, Martinez S, Brunet J, Alvaro T, Palacios J. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. lmmunohistochemical study of 153 cases. Histol Histopathol. 1995;10(3):531-9.
Published
2016-12-13
Issue
Vol 3 No 6 (2016): (Suppl) December
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).

 

Most read articles by the same author(s)

1 2 > >>